Carlos H Barrios Selected Research

Cyclophosphamide (Cytoxan)

1/2022	Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
10/2020	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlos H Barrios Research Topics

Disease

29	Breast Neoplasms (Breast Cancer) 01/2023 - 10/2005
27	Neoplasms (Cancer) 12/2023 - 02/2010
12	Triple Negative Breast Neoplasms 12/2023 - 11/2018
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2012
7	Renal Cell Carcinoma (Grawitz Tumor) 04/2023 - 02/2010
5	Disease Progression 11/2018 - 04/2013
5	Diarrhea 10/2017 - 12/2012
4	Neoplasm Metastasis (Metastasis) 01/2020 - 11/2015
4	Fatigue 01/2020 - 03/2012
3	Neutropenia 01/2020 - 09/2014
3	Nausea 12/2017 - 03/2016
3	Vomiting 12/2017 - 03/2016
2	Pathologic Complete Response 09/2022 - 01/2022
2	Exanthema (Rash) 02/2016 - 09/2014
1	Microsatellite Instability 09/2021
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2021
1	Pneumonia (Pneumonitis) 10/2020
1	Liver Failure 01/2020
1	Autoimmune Hepatitis 01/2020
1	Anemia 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Communicable Diseases (Infectious Diseases) 01/2019
1	Amenorrhea 01/2019
1	Body Weight (Weight, Body) 04/2018
1	Asthenia 10/2017
1	Headache (Headaches) 10/2017
1	Myocardial Infarction 03/2016
1	Stomach Neoplasms (Stomach Cancer) 03/2016
1	Hand-Foot Syndrome 02/2016
1	Febrile Neutropenia 02/2016
1	Brain Neoplasms (Brain Tumor) 01/2016
1	Ascites 08/2015
1	Carcinoma (Carcinomatosis) 08/2015

Drug/Important Bio-Agent (IBA)

13	Trastuzumab (Herceptin)FDA Link 01/2023 - 10/2005
11	atezolizumabIBA 12/2023 - 11/2018
10	Hormones (Hormone)IBA 01/2023 - 11/2015
8	taxaneIBA 12/2023 - 02/2016
8	130-nm albumin-bound paclitaxelIBA 12/2023 - 11/2018
6	Biomarkers (Surrogate Marker)IBA 12/2023 - 11/2019
6	human ERBB2 proteinIBA 01/2023 - 06/2017
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 09/2012
6	Capecitabine (Xeloda)FDA Link 01/2022 - 05/2010
5	Tyrosine Kinase InhibitorsIBA 01/2023 - 11/2015
5	neratinibIBA 01/2023 - 03/2016
5	B7-H1 AntigenIBA 01/2022 - 11/2018
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 09/2014
5	Sunitinib (Sutent)FDA Link 04/2018 - 05/2010
4	LigandsIBA 05/2024 - 10/2020
4	pembrolizumabIBA 12/2023 - 12/2020
4	Ado-Trastuzumab EmtansineIBA 01/2022 - 01/2019
4	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 08/2013
4	pertuzumabIBA 01/2022 - 06/2017
4	Gemcitabine FDA Link 01/2022 - 04/2010
4	Lapatinib (GW572016)FDA Link 01/2021 - 09/2014
3	CytokinesIBA 04/2023 - 02/2010
3	pazopanib FDA Link 04/2023 - 02/2010
3	PlatinumIBA 01/2021 - 08/2015
3	Monoclonal AntibodiesIBA 10/2020 - 10/2005
2	Immune Checkpoint InhibitorsIBA 12/2023 - 01/2021
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2020
2	NivolumabIBA 01/2021 - 04/2018
2	IpilimumabIBA 01/2021 - 04/2018
2	AnthracyclinesIBA 10/2020 - 01/2020
2	Estrogen ReceptorsIBA 01/2020 - 12/2012
2	Tumor Biomarkers (Tumor Markers)IBA 05/2019 - 01/2019
1	ipatasertibIBA 12/2023
1	ribociclibIBA 01/2023
1	Immunoglobulin G (IgG)IBA 10/2022
1	GlycosphingolipidsIBA 10/2022
1	Immunoglobulin M (IgM)IBA 10/2022
1	Conjugate VaccinesIBA 10/2022
1	Globo-HIBA 10/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Albumin-Bound Paclitaxel FDA Link 01/2022
1	entrectinibIBA 09/2021
1	larotrectinibIBA 09/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Darbepoetin alfa (Aranesp)FDA Link 01/2020
1	Aromatase InhibitorsIBA 01/2020
1	Formaldehyde (Formol)FDA Link 11/2019
1	ParaffinIBA 11/2019
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019
1	AfatinibIBA 01/2018
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 10/2017
1	Fulvestrant (Faslodex)FDA Link 10/2017
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 10/2017
1	Alanine Transaminase (SGPT)IBA 02/2016
1	Vinorelbine (Navelbine)FDA LinkGeneric 02/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2016

Therapy/Procedure

27	Therapeutics 12/2023 - 10/2005
18	Drug Therapy (Chemotherapy) 12/2023 - 10/2005
6	Adjuvant Chemotherapy 01/2023 - 10/2005
3	Immunotherapy 09/2022 - 01/2022
2	Radiotherapy 01/2020 - 03/2012
1	Neoadjuvant Therapy 09/2022
1	Precision Medicine 09/2021
1	Consolidation Chemotherapy 01/2018
1	Nephrectomy 01/2016